The recent JAMA Pediatrics study has revealed a crucial finding in the realm of infant RSV protection: nirsevimab's effectiveness wanes significantly after the first year. This discovery carries profound implications for public health strategies, particularly in regions where RSV is a prevalent concern. The study's methodology involved tracking infants who received nirsevimab in 2023 and 2024, as well as unimmunized infants, over a two-year period. The findings indicate that while nirsevimab provided a protective shield during the initial year, its efficacy did not persist into the second year, raising questions about the long-term sustainability of this approach to RSV prevention. This development underscores the need for ongoing research and the development of more robust RSV prevention strategies to safeguard infants from this potentially severe respiratory virus.
